Every Form 4 that United Therapeutics Corp (UTHR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow UTHR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UTHR filings page.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of company stock. On March 16, 2026, she sold 200 shares of Common Stock at an average price of $535.44 per share in a sale classified as an open-market transaction.
After this sale, she directly holds 4,445 shares of UNITED THERAPEUTICS Common Stock. According to a footnote, this transaction was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and on the same date sold 9,500 shares in open-market trades at weighted average prices between $535.43 and $542.04. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the transactions, she holds 7,150 shares directly and additional indirect holdings through her spouse and family trusts totaling several hundred thousand shares.
United Therapeutics Corp Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 12, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
That same day and on March 16, 2026, she completed open-market sales totaling 9,500 common shares at weighted average prices generally between $531.94 and $544.80. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following these trades, Rothblatt holds 8,414 shares of common stock directly. She also has indirect interests, including 166 shares held by her spouse and shares held in various family trusts, such as 324,518 shares in one trust where family members are beneficiaries.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options covering 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the same number of shares. On the same March 11, 2026, she sold 9,500 common shares in multiple open‑market transactions at prices ranging from $531.90 to $544.94, leaving 130 shares held directly.
The options exercised were originally granted on March 15, 2020 and were scheduled to expire on March 15, 2027. The filing also shows additional indirect holdings, including shares held by a spouse and in several family trusts, such as 324,518 and 258,117 shares reported as held by trusts. All option exercises and related sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is set to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in multiple open-market trades at prices generally between about $530 and $548 per share. These transactions on March 10, 2026 were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is designed to execute trades automatically over time. Following the sales, she holds 130 shares directly and also has substantial indirect holdings through family trusts, including 324,518 shares held by a trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On March 9, 2026, she exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and received 9,500 shares.
That same day, she sold 9,500 shares of common stock in a series of open-market trades, including 200 shares at $500.05 per share and 80 shares at $529.83 per share. After these trades, she held 130 shares directly, and also reported additional indirect holdings through her spouse and several family trusts.
The footnotes state that this option exercise and sale of resulting shares were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on March 6, 2026. She then sold 9,500 shares in multiple open-market transactions at prices reported between $471.96 and $484.27 per share.
The filing notes these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which runs until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following the sales, she holds 130 shares directly and additional indirect holdings through her spouse and family trusts.
UNITED THERAPEUTICS Corp director Judy D. Olian sold common stock in a planned transaction. On March 6, 2026, she completed an open-market sale of 200 shares of common stock at a price of $510 per share, leaving her with 4,645 shares held directly.
According to a footnote, this sale was made under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025. Such plans are designed to allow insiders to systematically sell shares over time according to predetermined instructions.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares on March 5, 2026, converting derivative securities into common stock at a reported exercise price of $146.03 per share.
On the same date, she sold a total of 9,500 common shares in a series of open-market transactions, with reported weighted-average prices ranging from $479.8871 to $487.9813, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly held 130 common shares, in addition to indirect holdings reported as 166 shares by spouse and 324,518, 258,117, 45,596 and 10,962 shares held by various family trusts.
UNITED THERAPEUTICS Corp executive Paul A. Mahon, EVP & General Counsel, reported exercising stock options and selling resulting shares. On March 5, 2026, he exercised 8,300 stock options at a reported price of $0.0000 per option, receiving 8,300 shares of common stock at a reported price of $146.0300 per share.
The filing shows multiple open-market sales totaling 8,300 shares of common stock on the same date at reported weighted average prices between about $479.4271 and $487.6520. A footnote states these option exercises and related sales were made under a pre-arranged 10b5-1 trading plan entered into on August 11, 2025. After these transactions, Mahon directly held 36,844 shares of common stock and 33,500 stock options as of March 5, 2026, including 63 shares acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt reported an insider transaction involving stock options and common shares. On March 4, 2026, she exercised 9,500 stock options (labeled as Stock Options) at a reported exercise price of $0.0000 per share, leaving her with 211,500 stock options held directly following the exercise.
The same day, she executed a series of open-market sales totaling 19,000 shares of Common Stock, with reported per‑share prices including $486.4229 and up to $497.0500. After these sales, she held 130 shares of Common Stock directly. Additional indirect Common Stock holdings are reported as 166 shares held by spouse and 324,518, 258,117, 45,596, and 10,962 shares held by various family trusts. A footnote states that the option exercise and related share sales were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
United Therapeutics Corp director Ray Kurzweil reported a set of transactions involving company stock. On March 4, 2026, he exercised a stock option for 4,910 shares, which resulted in acquiring 4,910 shares of common stock at a stated price per share of 101.8000. On the same date, he then sold 4,910 shares of common stock at a reported price per share of 489.0200. After these transactions, his directly owned common stock holdings were 12,670 shares.
UNITED THERAPEUTICS Corp director Tommy G Thompson reported multiple transactions on March 4, 2026. He exercised a stock option for 2,000 options, labeled as an exercise or conversion of a derivative security, resulting in 2,000 options held afterward.
On the same date, he acquired 2,000 shares of common stock through this option exercise at a price of $101.8000 per share, bringing his direct common stock holdings to 10,480 shares. He then executed an open-market sale of 2,000 common shares at a weighted average price of $489.4197 per share, leaving 8,480 directly held shares.
A footnote states that his direct holdings include 880 additional common shares to be issued on or about July 8, 2026 from previously vested RSUs for which receipt was deferred. Indirectly, 8,200 common shares are held by a trust and 5,800 common shares are held through a Family LLC associated with him.
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options for 20 shares on March 4, 2026, converting them into common stock at a price of $119.76 per share. He then sold 20 common shares in an open-market transaction at a weighted average price of $490.1685 per share.
The option exercise and subsequent sale were carried out under a pre-arranged Rule 10b5-1 trading plan that Causey entered into on September 30, 2025. The sale occurred in multiple trades, with individual prices ranging from $490.12 to $490.21, and left him with 4,190 common shares held directly.
United Therapeutics Chairperson and CEO Martine Rothblatt reported a mix of option exercises and stock sales. On March 3, 2026, she exercised 9,500 stock options, receiving an equal number of common shares, then sold 9,500 common shares in multiple open-market transactions.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the reported sales, she directly held 130 common shares, in addition to indirect holdings through her spouse and family trusts.
United Therapeutics Corp director Jan Malcolm reported an open-market sale of 50 shares of common stock on March 3, 2026 at a price of $509.20 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Malcolm beneficially owned 170 shares of common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a series of insider trades in the company’s common stock. On March 2, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
That same day, she conducted multiple open‑market sales totaling 9,500 shares of common stock, at reported weighted‑average prices generally between about $507 and $525 per share across numerous trades. The Form 4 notes these transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026.
The filing also reports indirect holdings of common stock through a spouse and various family trusts, where the reporting person or her immediate family share or hold investment power and are beneficiaries.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of common stock. She sold 200 shares on February 27, 2026 at an average price of $509.55 per share under a pre-arranged Rule 10b5-1 trading plan entered into on November 24, 2025. After this transaction, she directly owns 4,845 common shares.
United Therapeutics Corporation executive vice president and general counsel Paul A. Mahon reported equity awards tied to multi-year performance goals. He acquired 49,860 performance-based stock options and two tranches of performance-based restricted stock units covering 7,796 and 8,895 units, all at a grant price of $0 per unit.
The options were earned based on average cash profit margin for 2023-2025, while the restricted stock units were earned based on average revenue growth and clinical development performance over 2023-2025. All reported awards will vest on March 15, 2026, and each restricted stock unit converts into one share of common stock after vesting.
ROTHBLATT MARTINE A reported acquisition or exercise transactions in this Form 4 filing.
UNITED THERAPEUTICS Corp reported new performance-based equity awards for Chairperson & CEO Martine A. Rothblatt. She was credited with 207,720 stock options and two blocks of performance-based restricted stock units covering 32,499 and 37,080 units.
The options are tied to average cash profit margin during 2023–2025, while the RSUs are tied to average revenue growth and clinical development performance over the same 2023–2025 period. Performance outcomes were determined in early 2026, and all earned options and RSUs are scheduled to vest on March 15, 2026, with each RSU delivering one common share at vesting.
UNITED THERAPEUTICS Corp reported that President and COO Michael Benkowitz acquired equity awards tied to multi‑year performance goals. On March 15, 2023 he was granted 99,720 performance-based stock options earned from a three-year cash profit margin target for 2023-2025, which will vest on March 15, 2026.
He was also granted 15,592 performance-based restricted stock units tied to average revenue growth for 2023-2025 and 17,790 performance-based restricted stock units tied to clinical development performance for 2023-2025; both awards were earned based on performance and will vest on March 15, 2026. Each restricted stock unit converts into one share of common stock after vesting.
United Therapeutics reported that CFO and Treasurer James Edgemond acquired new equity awards made up of stock options and performance-based restricted stock units. He received 58,170 stock options and two tranches of restricted stock units totaling 9,098 and 10,380 units.
The stock options are tied to a three-year performance condition based on average cash profit margin during 2023-2025, with performance determined in February 2026. One restricted stock unit grant is tied to average revenue growth during 2023-2025, with performance also determined in February 2026, while the other is tied to clinical development performance during 2023-2025, determined in January 2026.
All earned awards will vest on March 15, 2026. Each restricted stock unit gives the right to receive one share of United Therapeutics common stock after vesting, and the units do not have an expiration date.
UNITED THERAPEUTICS Corp director Christopher Causey reported option exercises and a share sale. He exercised stock options for 1,000 shares on February 25, 2026, converting derivative securities at a stated price of $0.0000 and acquiring 1,000 shares of common stock at $119.7600 per share.
On the same date, he sold 1,000 shares of common stock at $520.0000 per share in an open-market transaction. After these transactions, he directly held 4,190 shares of common stock and 6,320 stock options. The exercise and subsequent sale were made under a Rule 10b5-1 trading plan entered into on September 30, 2025.
UNITED THERAPEUTICS Corp president and COO Michael Benkowitz reported option exercises and related sales of common stock through trusts on February 23, 2026. Trusts associated with him exercised options for 9,375 and 5,065 shares, then sold those same amounts in open-market transactions at $472.126 per share.
The activity was carried out under a Rule 10b5-1 trading plan that was previously established and these are the final transactions under that plan. Following these indirect trust transactions, Benkowitz directly holds 2,648 shares of United Therapeutics common stock.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares in a planned transaction. He exercised options for 8,300 shares of common stock at a price of $146.03 per share and received the underlying shares.
On the same date, he sold 8,300 shares of common stock in multiple open-market trades at weighted average prices ranging from about $471 to $479 per share under a pre-arranged Rule 10b5-1 plan entered on August 11, 2025. After these transactions, he directly owned 36,781 shares of UNITED THERAPEUTICS common stock.
UNITED THERAPEUTICS Corp president and COO Michael Benkowitz reported option exercises and related sales of common stock held in family trusts. On February 17, 2026, trusts associated with him exercised options for 14,625 and 7,875 shares, then sold the resulting 22,500 shares in open-market transactions at $480.7536 per share under a pre-established Rule 10b5-1 trading plan entered into on June 3, 2025. After these indirect transactions, Benkowitz continued to hold 2,648 shares of common stock directly.
United Therapeutics director Malcolm Jan reported an open-market sale of company stock. On February 17, 2026, he sold 50 shares of United Therapeutics common stock at a price of $474.68 per share in a transaction coded as an open-market sale.
After this transaction, Jan directly holds 220 shares of United Therapeutics common stock. The sale was carried out under a pre-established Rule 10b5-1 trading plan that he entered into on September 11, 2025, which automates trades according to preset instructions.
United Therapeutics Corporation’s president and COO, Michael Benkowitz, reported option exercises and related sales of United Therapeutics (UTHR) stock through trusts on February 9, 2026. Two trusts beneficially owned by him exercised stock options for 14,625 shares at $117.76 and 7,875 shares at $146.03, then sold the same numbers of shares at $474.6527 per share. The filing notes these transactions were executed under a Rule 10b5-1 trading plan entered into on June 3, 2025. After these indirect transactions, he also reports direct beneficial ownership of 2,648 common shares.
United Therapeutics EVP and General Counsel Paul A. Mahon reported an option exercise and related share sales. On February 5, 2026, he exercised 8,300 stock options at an exercise price of $146.03 per share and sold the resulting shares in multiple trades under a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025.
Sale prices ranged from weighted averages of $480.9191 to $485.5179 across several transactions. Following these transactions, Mahon directly owned 36,781 shares of United Therapeutics common stock and 50,100 stock options.
United Therapeutics director Malcolm Jan reported a small planned share sale. On 02/03/2026, he sold 50 shares of United Therapeutics common stock at $474.23 per share in an open-market transaction coded "S." The sale was made under a pre-arranged Rule 10b5-1 trading plan that he entered into on September 11, 2025.
After this transaction, Jan beneficially owned 270 shares of United Therapeutics common stock, held in direct ownership form.
United Therapeutics president and COO Michael Benkowitz reported pre‑planned option exercises and share sales through family trusts. On February 2, 2026, trusts associated with him exercised 14,625 stock options at $117.76 and 7,875 options at $146.03, then sold the resulting common shares at $470.9524 per share under a Rule 10b5‑1 trading plan entered on June 3, 2025. After these indirect transactions, he continued to hold 2,648 shares of common stock directly, while retaining beneficial ownership and investment/voting power over the trust holdings as described in the filing.
United Therapeutics Corporation’s President and COO Michael Benkowitz reported multiple pre-planned insider transactions involving company stock held in trusts associated with him. On January 20, 2026, a trust exercised 7,875 stock options at an exercise price of $146.03 per share and sold the resulting common shares in a series of trades at weighted-average prices ranging from about $456.8652 to $470.755, reducing that trust’s common stock position to zero.
On January 26, 2026, a trust where he and his spouse are co‑trustees exercised 14,625 stock options at an exercise price of $117.76 per share and sold 14,625 common shares at a weighted-average price of $471.9081. A second trust exercised 7,875 stock options at $146.03 per share and sold 7,875 common shares at $471.9081. The filing notes these option exercises and share sales were made under a Rule 10b5‑1 trading plan entered into on June 3, 2025. Following these transactions, trusts associated with Benkowitz continued to hold stock options, and he also held 2,648 shares of common stock directly.
United Therapeutics Corp’s president and COO Michael Benkowitz reported an automatic transaction by a trust associated with him. On January 20, 2026, the trust exercised stock options for 14,625 shares of common stock at an exercise price of $146.03 per share and received 14,625 shares.
That same day, the trust sold all 14,625 shares in multiple trades at weighted‑average prices between $456.34 and $470.70, under a Rule 10b5‑1 trading plan adopted on June 3, 2025. After these sales, the trust held 0 shares of common stock, while Benkowitz held 2,648 shares directly and 67,875 stock options indirectly through the trust, over which he and his spouse share investment and voting power.
United Therapeutics Corporation disclosed that new director Kevin Tracey received a grant of restricted stock units on January 21, 2026. The award covers 1,220 restricted stock units, each representing the right to receive one share of United Therapeutics common stock after vesting. The units were granted at a price of $0.00 in connection with his appointment to the Board of Directors under the company’s Non-Employee Director Compensation Program.
The award becomes fully vested on the one-year anniversary of the grant date, January 21, 2027. Following this grant, Tracey beneficially owns 1,220 derivative securities in the form of restricted stock units, held directly.
United Therapeutics director Malcolm Jan reported a small planned stock sale. On January 16, 2026, he sold 50 shares of United Therapeutics common stock at $460.98 per share in an open market transaction coded as a sale. The filing notes that this trade was executed under a pre-established Rule 10b5-1 trading plan that the reporting person entered into on September 11, 2025, which is designed to allow insiders to sell shares according to a preset schedule. After this transaction, he beneficially owned 320 shares of the company’s common stock in direct ownership.
United Therapeutics Corp EVP & General Counsel Paul A. Mahon reported an option exercise and related share sales in company stock. On January 15, 2026, he exercised a stock option for 8,300 shares of common stock at an exercise price of $146.03 per share. The exercise and sale were made under a pre-arranged Rule 10b5-1 trading plan that he entered into on August 11, 2025.
On the same day, he reported multiple open-market sales of common stock in several blocks, including transactions of 1,439 shares at $468.324, 1,307 shares at $470.3663, 407 shares at $472.2826, 3,531 shares at $469.3392, 1,576 shares at $471.4401, and 40 shares at $474.74. After these transactions, Mahon directly held 36,781 shares of United Therapeutics common stock and 58,400 stock options remained beneficially owned following the reported option exercise.
United Therapeutics Corporation President and COO Michael Benkowitz reported option exercises and related share sales in United Therapeutics (UTHR) on January 12, 2026.
Trusts associated with him exercised 14,625 stock options at $117.76 per share and 7,875 stock options at $146.03 per share, then sold the same numbers of common shares at $479.5056 per share. These transactions were carried out under a Rule 10b5-1 trading plan entered into on June 3, 2025.
After these trades, one trust held 82,500 stock options and another held 44,440 stock options, and Benkowitz also held 2,648 shares of common stock directly. The filing notes that one trust is co‑managed by him and his spouse, while another is managed solely by him for the benefit of family members.
United Therapeutics president and COO Michael Benkowitz reported an option exercise and related share sales made through a trust. On January 5, 2026, a trust for his benefit exercised 14,625 stock options at an exercise price of $117.76 per share, receiving the same number of United Therapeutics common shares. The trust then sold those 14,625 shares in a series of open-market transactions at weighted-average prices that include $480.6821 and $494.2723, fully disposing of the shares acquired from the exercise.
The filing states that this option exercise and subsequent sales were carried out under a Rule 10b5-1 trading plan entered into on June 3, 2025. Following these transactions, a trust associated with Benkowitz continues to hold 97,125 stock options, and he also reports 2,648 shares of common stock held directly.
United Therapeutics Corp’s president and COO Michael Benkowitz, through a family trust, reported an option exercise and related share sales. On January 5, 2026, the trust exercised 7,875 stock options at an exercise price of $146.03 per share, receiving the same number of common shares. Those 7,875 shares of common stock were then sold in multiple open‑market transactions at weighted‑average prices ranging from about $480.32 to $494.41, all reported as indirect ownership "by Trust."
The filing states that the exercise and sales were made under a Rule 10b5‑1 trading plan entered into on June 3, 2025. After these sales, the trust no longer holds common stock, while Benkowitz is shown as directly owning 2,648 shares of common stock and indirectly holding 52,315 stock options through the trust.
United Therapeutics Corporation director Christopher Causey reported an option exercise and share sale. On January 6, 2026, he exercised stock options for 1,000 shares of common stock at an exercise price of $119.76 per share and acquired the underlying shares.
On the same date, he sold 1,000 shares of United Therapeutics common stock at a reported price of $510 per share. After these transactions, he directly owned 4,190 shares of common stock and 7,320 stock options. The filing notes that the option exercise and sale were carried out under a Rule 10b5-1 trading plan adopted on September 30, 2025.
United Therapeutics Corporation’s CFO and Treasurer reported an option exercise and related share sales. On December 15, 2025, the executive exercised stock options for 3,517 shares of common stock at an exercise price of $146.03 per share and acquired those shares.
On the same date, the executive sold United Therapeutics common stock in multiple open-market transactions, with disclosed weighted average sale prices including $491.525 and $500.303 per share. After these transactions, the executive directly beneficially owns 8,142 shares of United Therapeutics common stock.
The option exercise and subsequent sales were carried out pursuant to a Rule 10b5-1 trading plan entered into on August 5, 2025. The report also corrects a prior administrative error by now including 24 shares acquired on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan in the executive’s reported holdings.
United Therapeutics’ Chairperson & CEO, who is also a director, reported stock option exercises and related common stock sales under a pre-arranged Rule 10b5-1 trading plan. On December 15 and 16, 2025, the reporting person exercised 4,000 stock options at an exercise price of $120.26 on each day and sold the resulting shares in multiple open-market transactions at prices including $491.77, $495.1384, $492.4938, $494 and $497.17.
After these transactions, the reporting person held 130 shares of common stock directly, plus indirect holdings of 166 shares through a spouse and additional shares through family trusts, including 324,518, 258,117, 45,596 and 10,962 shares. The trades were made pursuant to a 10b5-1 trading plan entered on May 2, 2025, which will continue until the earlier of the exhaustion of a 294,000-share stock option tranche expiring on March 15, 2026 or December 31, 2025.
United Therapeutics President and COO reported insider transactions on 12/15/2025. The filing shows exercises of stock options into 14,625 and 7,875 shares of common stock held in family-related trusts, at exercise prices of $117.76 and $146.03 per share.
The common shares were then sold the same day in multiple trades under a Rule 10b5-1 trading plan entered on June 3, 2025, including sales at weighted average prices of $491.1817 and $500.3052. After these transactions, the trusts reported no remaining common shares, while 141,000 and 6,190 stock options remain indirectly owned.
United Therapeutics Corporation director reports stock option exercise and share sale. On 12/15/2025, the reporting person exercised 1,000 stock options at an exercise price of $101.80 per share and acquired an equal number of United Therapeutics common shares. On the same date, they sold 1,000 shares of common stock at a weighted average price of $495.9539 per share, with individual trades executed between $495.64 and $496.09. Following these transactions, the director beneficially owns 1,490 shares directly and 1,100 shares indirectly through a trust, as well as 3,910 stock options with a $101.80 exercise price expiring on 06/21/2026.
United Therapeutics reported that a company director sold 50 shares of common stock on 12/11/2025 at a price of $482.98 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that the insider entered into on September 11, 2025. Following this sale, the director beneficially owns 470 shares of United Therapeutics common stock held directly.
United Therapeutics Corp’s Executive Vice President and General Counsel reported an insider transaction involving stock options and common shares. On 12/11/2025, the officer exercised stock options for 11,000 shares of common stock at an exercise price of $146.03 per share and then sold common stock in several market transactions at weighted average prices including $482.2219 and $487.366 per share.
The activity was carried out under a pre-arranged Rule 10b5-1 trading plan that the reporting person entered into on December 24, 2024. After these transactions, the officer directly owned 36,781 shares of United Therapeutics common stock and held 20,250 stock options that remain outstanding.
United Therapeutics Corporation’s chairperson and CEO reported option exercises and related share sales in December 2025. On 12/11/2025 and 12/12/2025, the reporting person exercised stock options for 4,000 shares of common stock on each day at an exercise price of $120.26 per share and sold the same number of shares in the market.
The reported sales were executed at weighted average prices of $483.1213, $484.3036, $485.14, $489.9533 and $490.9772, pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on May 2, 2025. Following these transactions, the reporting person holds 130 shares directly, 166 shares indirectly through a spouse, and additional indirect interests through several family trusts, including positions of 324,518, 258,117, 45,596 and 10,962 shares.
United Therapeutics Corporation reported insider activity by its CFO and Treasurer involving stock options and common shares. On 12/08/2025, the officer exercised a stock option for 21,000 shares of common stock at an exercise price of $146.03 per share, increasing direct holdings before sales.
That same day, the officer sold United Therapeutics common stock in a series of open-market transactions coded as sales, with weighted average prices reported from about $475.08 to $486.71 per share, executed in multiple trades at price ranges disclosed in the notes. After these transactions, the officer directly owned 8,142 shares of common stock. The filing states that the option exercise and subsequent share sales were made under a pre-arranged Rule 10b5-1 trading plan that was entered into on August 5, 2025.
United Therapeutics Corporation (UTHR) reported insider activity by its CFO and Treasurer on a Form 4. On 11/24/2025, the executive exercised 21,000 stock options at an exercise price of $146.03 per share, converting them into common stock. That same day, multiple blocks of common shares were sold in market transactions, with weighted average sale prices reported in ranges generally around $466.72 to $482.42 per share. After these transactions, the reporting person directly held 8,142 shares of United Therapeutics common stock. The filing notes that the option exercise and subsequent sales were carried out under a Rule 10b5-1 trading plan entered into on August 5, 2025, which is a pre-arranged plan intended to allow insiders to trade shares over time according to preset instructions.
United Therapeutics (UTHR) reported insider equity activity by its President and COO on 11/24/2025. Through trusts, the reporting person exercised stock options for 2,625, 12,000, and 7,875 shares of common stock at exercise prices of $117.76, $135.42, and $146.03 per share, respectively.
The same numbers of shares were then sold at a price of $473.6569 per share by the relevant trusts under a Rule 10b5-1 trading plan entered into on June 3, 2025. After these trust transactions, the reporting person shows 2,648 shares of United Therapeutics common stock held directly.